COMP360 REMS & Future Practice— FYI
For Background
COMP360 is Compass Pathways' proprietary synthetic, GMP-grade psilocybin formulation, developed primarily for treatment-resistant depression (TRD). Key milestones:
The FDA designated psilocybin for TRD as a Breakthrough Therapy in 2018. Compass has now asked to meet with the FDA to discuss a rolling NDA submission, targeting sometime between October and December 2026, which would make COMP360 potentially the first "classic" psychedelic cleared in the U.S. BioPharma Dive
More than 1,000 patients have been treated with COMP360 across studies, spanning toxicology, safety, and CMC work.
Beyond TRD, COMP360 is also under evaluation for PTSD and anorexia nervosa, with encouraging early-phase results in both.
Why a REMS Is Expected (Risk Evaluation and Mitigation Strategies)
A REMS is a drug safety program the FDA can require for medications with safety concerns, to help ensure benefits outweigh risks. It focuses on preventing, monitoring, and/or managing specific serious risks through education and enforced behaviors — not on mitigating all adverse events.
Psilocybin has been recommended for rescheduling as a Schedule IV controlled substance with a REMS if approved by regulatory agencies.
The FDA has signaled clearly that a REMS will be required for COMP360.
Based on FDA guidance, the Spravato (esketamine) REMS precedent, and Compass's own disclosures, the REMS for COMP360 would likely include the following elements:
1. Certified Prescriber Requirement (ETASU)
A REMS would include certified prescribers, meaning only specially trained and enrolled clinicians could prescribe COMP360. The FDA has indicated it is considering developing a class-wide REMS for psychedelics given the complexity of the risks involved, and provider training or certification is one of the primary tools being considered.
2. Certified/Enrolled Treatment Facilities
The FDA has directed Compass to look at the Spravato REMS as a reference point, and commercial delivery would likely be comparable in practice, with a licensed healthcare provider on site and a prescriber available during treatment. Only enrolled sites meeting structural and staffing requirements would be permitted to administer COMP360.
3. On-Site Monitoring During Administration
Trained facilitators would need to be present during the approximately 6-hour drug administration session.
4. Structured Psychological Support (Integration Sessions)
The REMS would also likely require structured post-experience integration sessions following the dosing day. This is consistent with how COMP360 was administered in clinical trials, with preparatory and integration therapy built around the drug session.
5. Patient Enrollment / Monitoring
By analogy with Spravato, patients would likely need to be enrolled in the REMS program, with post-dose observation periods required before discharge. Esketamine's REMS requires patients to be monitored for 2 hours after administration for safety. COMP360's ~6-hour session duration would require more extended monitoring.
6. No Home Use / Restricted Distribution
COMP360 would almost certainly be restricted to in-clinic administration only, with no take-home dispensing. Distribution would flow through certified pharmacies to certified sites.
Commercial Feasibility Debate
A key industry concern is whether requiring substantial psychotherapeutic support around each session — potentially two therapists for 4–8 hours — would be a "deal breaker" for most clinics that lack such capacity. However, Compass has described commercial delivery as likely requiring a licensed healthcare provider on site and a prescriber available, rather than the granular in-room requirements used in clinical trial protocols — suggesting a pragmatic REMS structure. Analysts note that a REMS is not inherently a barrier — Spravato also requires one and has grown to over $1 billion in annual sales with thousands of certified clinics across the country.
In short, the COMP360 REMS is expected to closely mirror the Spravato model: certified prescribers, certified treatment centers, mandatory on-site monitoring during the full session, and structured integration support, but adapted for a longer (~6-hour) psilocybin administration window.
Sources
https://www.psychiatrictimes.com/view/developments-in-psychedelic-regulation-for-comp360
